Terns Pharmaceuticals reported early ASH data showing its next‑generation chronic myeloid leukemia candidate TERN‑701 achieved a 64% major molecular response rate at 24 weeks across four escalating doses in heavily pretreated patients. STAT covered the presentation and noted safety was manageable with no dose‑limiting toxicities in the dataset released. The response rates compare favorably to historical Phase I results for Novartis’ Scemblix and prompted analysts to position TERN‑701 as a potential successor in CML therapies. Company comments and meeting slides emphasized biomarker depth and durability as drivers for moving the program forward. Investors and competitors will watch for confirmatory data and dose selection that could inform registration strategy and positioning versus established BCR‑ABL inhibitors.